Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Dec 1;29(34):4534-40.
doi: 10.1200/JCO.2010.33.0670. Epub 2011 Oct 24.

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma

Heribert Juergens  1 , Najat C Daw, Birgit Geoerger, Stefano Ferrari, Milena Villarroel, Isabelle Aerts, Jeremy Whelan, Uta Dirksen, Mary L Hixon, Donghua Yin, Tao Wang, Stephanie Green, Luisa Paccagnella, Antonio Gualberto
Affiliations
Clinical Trial

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma

Heribert Juergens et al. J Clin Oncol. .

Abstract

Purpose: Patients with Ewing sarcoma (ES) with metastases and those who relapse fare poorly and receive therapies that carry significant toxicity. This phase 1/2 study was conducted to evaluate the efficacy of figitumumab in advanced ES.

Patients and methods: Patients with sarcoma 10 to 18 years old were enrolled in two dose escalation cohorts (20 and 30 mg/Kg intravenously every 4 weeks) in the phase 1 portion of the study. Patients with ES 10 years old or older were enrolled in the phase 2 portion of the study. The primary phase 2 objective was objective response rate (ORR).

Results: Thirty-one patients with ES (n = 16), osteosarcoma (n = 11), or other sarcomas (n = 4) were enrolled in the phase 1 portion of the study. Dose escalation proceeded to 30 mg/kg every 4 weeks with no dose-limiting toxicity identified. In the phase 2 portion of the study, 107 patients with ES received figitumumab at 30 mg/kg every 4 weeks for a median of 2 cycles (range, 1 to 16). Sixty three percent of phase 2 patients had received at least three prior treatment regimens. Of 106 evaluable patients, 15 had a partial response (ORR, 14.2%) and 25 had stable disease. Median overall survival was 8.9 months. Importantly, patients with a pretreatment circulating free insulin-like growth factor (IGF) -1 lower than 0.65 ng/mL (n = 14) had a median OS of 3.6 months, whereas those with a baseline free IGF-1 ≥ 0.65 ng/mL (n = 84) had a median OS of 10.4 months (P < .001).

Conclusion: Figitumumab had modest activity as single agent in advanced ES. A strong association between pretreatment serum IGF-1 and survival benefit was identified.

Trial registration: ClinicalTrials.gov NCT00560235.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Phase 2 schema. ES, Ewing sarcoma; F, figitumumab.
Fig 2.
Fig 2.
Kaplan-Meier curves for (A) progression-free survival and (B) overall survival. 95% CI boundaries are for all phase 2 study patients.
Fig 3.
Fig 3.
Association of free and total insulin-like growth factor (IGF) with patient survival. (A) Kaplan-Meier plots for overall survival (OS) of patients with a baseline (cycle 1 day predose) free IGF-1 lower than 0.65 ng/mL (n = 14) versus ≥ 0.65 ng/mL (n = 84). (B) Kaplan-Meier plots for OS of patients with a baseline total IGF-1 lower than 110 ng/mL (n = 17) versus ≥ 110 ng/mL (n = 81). (C) Kaplan-Meier plots for OS by quartile of baseline (cycle 1 day predose) free IGF-1 levels.
See this image and copyright information in PMC

Comment in

References

    1. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer. 2003;3:685–694. - PubMed
    1. Fletcher CDM, Unni KK, Mertens F. World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002.
    1. Prieur A, Tirode F, Cohen P, et al. EWS/FLI-1 silencing and geneprofiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004;24:7275–7283. - PMC - PubMed
    1. Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem. 1997;272:30822–30827. - PubMed
    1. Olmos D, Tan DS, Jones RL, et al. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: Twenty years from the bench to the bedside. Cancer J. 2010;16:183–194. - PubMed

Publication types

Associated data